For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
LPI (LP Information)' newest research report, the "Glucagon Like Peptide-1 (GLP-1) Agonists Industry Forecast" looks at past sales and reviews total world Glucagon Like Peptide-1 (GLP-1) Agonists sales in 2022, providing a comprehensive analysis by region and market sector of projected Glucagon Like Peptide-1 (GLP-1) Agonists sales for 2023 through 2029. With Glucagon Like Peptide-1 (GLP-1) Agonists sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Glucagon Like Peptide-1 (GLP-1) Agonists industry.
This Insight Report provides a comprehensive analysis of the global Glucagon Like Peptide-1 (GLP-1) Agonists landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Glucagon Like Peptide-1 (GLP-1) Agonists portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Glucagon Like Peptide-1 (GLP-1) Agonists market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Glucagon Like Peptide-1 (GLP-1) Agonists and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Glucagon Like Peptide-1 (GLP-1) Agonists.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market size is projected to grow from US$ 8624.4 million in 2022 to US$ 21310 million in 2029; it is expected to grow at a CAGR of 21310 from 2023 to 2029.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry by 68% market shares.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44%. The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28%.
This report presents a comprehensive overview, market shares, and growth opportunities of Glucagon Like Peptide-1 (GLP-1) Agonists market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- Exenatied
- Liraglutide
- Lixisenatide
- Albiglutide
- Dulaglutide
Segmentation by application
- Hospital
- Pharmacy
- Other
The below companies that are profiled
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Novo Nordisk
- AstraZeneca
- Eli Lily
- GSK
- Sanofi
- Bristol-Myers Squibb
- Amylin
Key Questions Addressed in this Report
What is the 10-year outlook for the global Glucagon Like Peptide-1 (GLP-1) Agonists market?
What factors are driving Glucagon Like Peptide-1 (GLP-1) Agonists market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Glucagon Like Peptide-1 (GLP-1) Agonists market opportunities vary by end market size?
How does Glucagon Like Peptide-1 (GLP-1) Agonists break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?